Videos / Orforglipron: Australia’s first non-peptide oral GLP-1
In this Product Explainer, Endocrinologist Dr Ted Wu examines how Orforglipron broadens access to GLP-1 therapy with an oral formulation, reviewing efficacy data, safety findings, and practical guidance for use in clinical practice (6 mins).

Oral GLP1s – What GPs Need to Know

The New Oral Medications for Obesity – A Practical Guide for GPs

Menstrual Migraine

GLP1s and Muscle Mass – What Does the Evidence Show?

expert
Senior Specialist Endocrinologist; Director, Royal Prince Alfred Hospital Diabetes Centre; Director of Physician Training, Royal Prince Alfred Hospital, Sydney

Lilly supports independent education on Healthed. Opt in to receive updates on relevant Lilly products, resources and events — directly, and only when there’s something worth sharing.